Axxam enters into a research collaboration with The University of Texas MD Anderson Cancer Center for Assay Development and High Throughput Screening of selected targets in oncology
June 18th, 2015 – Axxam SpA (Milan/Italy), a leading provider of discovery services, has entered into a multi-year collaboration with the Institute for Applied Cancer Science (IACS) at The University of Texas MD Anderson Cancer Center (MD Anderson). The aim of the collaboration is to identify lead chemical matters against novel oncology targets provided by MD Anderson. The collaboration leverages Axxam’s expertise in assay development, Axxam’s fully automated screening platforms and access to Axxam’s novel compound collection AxxDiv2.0. The collaboration builds on a strong working relationship between Axxam and MD Anderson.